Grant-backed validation Leverage the recent $5M French government grant to position Eligo Bioscience as a validated partner for public sector and European funder-led initiatives, highlighting grant-backed momentum to secure collaboration on topical gene delivery and microbiome-focused therapeutics.

Microbiome focus Target collaborations around microbiome precision-editing and skin-resident bacteria platforms, offering opportunities for partnerships with contract research organizations, clinical researchers, and pharma seeking localized biologics delivery and microbiome-modulating therapies.

Early-stage scale With a modest headcount and $75M in funding, position Eligo as a nimble partner for pilot programs, co-development, or milestone-driven collaborations that leverage fast decision cycles and reduced overhead for early-stage clinical or preclinical initiatives.

Topical delivery niche Emphasize the topical gene delivery platform as a differentiator to engage dermatology, dermatologic devices, and biotech firms interested in local production of biologics, enabling joint development toward topical or localized therapies.

Global partner potential Highlight France/EU funding exposure and international relevance to attract regional partners, advisors, or distributors seeking to expand microbiome-focused offerings with a European-backed, innovation-driven collaborator.